The U.S. Food and Drug Administration panel has set out to review Arcoxia, Merck & Co. Inc.'s replacement pain reliever drug for Vioxx which was recalled back in 2004. In a meeting set for April 12, 2007, the panel expects to discuss the safety and effectiveness of Arcoxia which is being heavily pushed by Merck for FDA approval. Of note worthy concern, Arcoxia, like Vioxx and Bextra, is a cox-2...